Hematologic Malignancy
Peripheral T-Cell Lymphoma, Not Otherwise Specified
CI-CAN-00008233Explore in graph →
Hematologic72 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008233Explore in graph →
Clinical trials
299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (41)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | recruiting | Phase 3 | 150 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06724237 | Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | recruiting | Phase 3 | 294 | Eastern Cooperative Oncology Group |
| 2 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT06072131 | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL(CRESCENDO) | recruiting | Phase 3 | 504 | Acrotech Biopharma Inc.INDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07234162 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | recruiting | Phase 3 | 218 | Dizal PharmaceuticalsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07414758 | Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy(T-START-M1) | recruiting | Phase 3 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07389616 | A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | recruiting | Phase 2 / Phase 3 | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07258680 | BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas(BrEto-TCL) | enrolling by invitation | Phase 3 | 114 | N.N. Petrov National Medical Research Center of OncologyOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT04668690 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL | active not recruiting | Phase 3 | 193 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 31, 2025 | clinicaltrials |
| NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 606 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | withdrawn | Phase 2 / Phase 3 | 0 | Portola PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT01796002 | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | completed | Phase 3 | 421 | The Lymphoma Academic Research OrganisationOTHER | 8 | Jan 10, 2023 | clinicaltrials |
| NCT01420679 | Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients | terminated | Phase 3 | 21 | Spectrum Pharmaceuticals, IncINDUSTRY | 13 | Nov 19, 2021 | clinicaltrials |
| NCT04880746 | Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | unknown | Phase 3 | 266 | Ruijin HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT03349333 | A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL | completed | Phase 3 | 85 | Mundipharma (China) Pharmaceutical Co. LtdINDUSTRY | 1 | Oct 1, 2019 | clinicaltrials |
| NCT03952572 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 3 | 244 | Peking UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT03553537 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unknown | Phase 3 | 100 | Southwest Hospital, ChinaOTHER | 0 | Jun 12, 2018 | clinicaltrials |
| NCT03023358 | Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | unknown | Phase 3 | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT01355783 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma | withdrawn | Phase 3 | 0 | Eisai Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00725231 | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP(A-CHOP-14) | unknown | Phase 3 | 274 | University of GöttingenOTHER | 1 | May 7, 2012 | clinicaltrials |
| NCT00970385 | Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma(LTP) | completed | Phase 3 | 95 | University Hospital, GrenobleOTHER | 1 | Sep 9, 2009 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials